Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers
- PMID: 20127405
- DOI: 10.1007/s10549-010-0761-y
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers
Abstract
The purpose of this article is to evaluate the prognostic value of androgen receptor (AR) expression in patients with estrogen receptor (ER)-positive breast cancer, treated with endocrine therapy, with or without the addition of chemotherapy. A consecutive series of 953 patients with ER-positive breast cancer, treated between 1998 and 2003, was selected. Repeated immunohistochemistry confirmed the expression of ER in the tumor of 938 patients. AR expression was measured by immunohistochemistry. The Kaplan-Meier method, logrank test and multivariate Cox models were used to explore the impact of AR expression on time to relapse (TTR) and disease specific survival (DSS) in all patients and in subgroups treated with chemo-endocrine therapy or endocrine therapy alone. AR immunoreactivity was assessable in 859 tumors and positive in 609 (70.9%). AR expression was a significant marker of good prognosis for TTR (P = 0.001) and DSS (P < 0.001). This effect was particularly evident in the group of patients receiving chemo-endocrine therapy (TTR (P = 0.015) and DSS (P < 0.001)). Cox models confirmed AR as an independent variable for both TTR (P = 0.003, HR 0.444, 95%CI 0.258-0.765) and DSS (P < 0.001, HR 0.135, 95%CI 0.054-0.337). Thus, we focused on ER-positive luminal B breast cancer that may be selected for chemotherapy because of their more aggressive immunophenotype. In this subset AR expression identified a group of patients with better prognosis for TTR (P = 0.017, HR 0.521, 95%CI 0.306-0.888) and DSS (P = 0.001, HR 0.276, 95% CI 0.130-0.588). AR expression is an independent prognostic factor of better outcome in patients with ER-positive breast cancers.
Comment in
-
The androgen receptor in breast cancer: learning from the past.Breast Cancer Res Treat. 2010 Dec;124(3):619-21. doi: 10.1007/s10549-010-0864-5. Epub 2010 Mar 31. Breast Cancer Res Treat. 2010. PMID: 20354779 No abstract available.
Similar articles
-
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. doi: 10.1093/jnci/djn309. Epub 2008 Sep 23. J Natl Cancer Inst. 2008. PMID: 18812550 Free PMC article.
-
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61. doi: 10.1093/jnci/dji249. J Natl Cancer Inst. 2005. PMID: 16145046
-
Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers.Breast Cancer Res Treat. 2012 May;133(1):311-20. doi: 10.1007/s10549-011-1950-z. Epub 2012 Jan 10. Breast Cancer Res Treat. 2012. PMID: 22231421
-
Adjuvant chemotherapy in luminal breast cancers.Breast. 2011 Oct;20 Suppl 3:S128-31. doi: 10.1016/S0960-9776(11)70309-5. Breast. 2011. PMID: 22015279 Review.
-
Disease related indicators for a proper choice of adjuvant treatments.Breast. 2011 Oct;20 Suppl 3:S162-4. doi: 10.1016/S0960-9776(11)70317-4. Breast. 2011. PMID: 22015287 Review.
Cited by
-
Androgen receptor as a targeted therapy for breast cancer.Am J Cancer Res. 2012;2(4):434-45. Epub 2012 Jun 28. Am J Cancer Res. 2012. PMID: 22860233 Free PMC article.
-
Breast Cancer: Targeting of Steroid Hormones in Cancerogenesis and Diagnostics.Int J Mol Sci. 2021 May 30;22(11):5878. doi: 10.3390/ijms22115878. Int J Mol Sci. 2021. PMID: 34070921 Free PMC article. Review.
-
Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.J Natl Cancer Inst. 2019 Jul 1;111(7):700-708. doi: 10.1093/jnci/djy173. J Natl Cancer Inst. 2019. PMID: 30445651 Free PMC article.
-
Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.Cancer Res. 2015 Jan 15;75(2):405-14. doi: 10.1158/0008-5472.CAN-14-2475. Epub 2014 Dec 5. Cancer Res. 2015. PMID: 25480943 Free PMC article.
-
Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.Oncotarget. 2017 May 2;8(18):30552-30562. doi: 10.18632/oncotarget.15547. Oncotarget. 2017. PMID: 28430630 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous